SAWAI PHARMACEUTICAL CO.LTD. — Atorvastatin Importer Profile
Pharmaceutical Importer · #15 buyer for Atorvastatin · $2.4M import value · 50 shipments · JAPAN · DGFT Verified
SAWAI PHARMACEUTICAL CO.LTD. is the #15 importer of Atorvastatin from India with $2.4M in import value and 50 verified shipments. SAWAI PHARMACEUTICAL CO.LTD. holds a 0.3% market share in Atorvastatin imports based in JAPAN. The company sources from 1 verified supplier across 43 formulations shipped to 1 country.
SAWAI PHARMACEUTICAL CO.LTD. — Atorvastatin Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Atorvastatin to SAWAI PHARMACEUTICAL CO.LTD.?
Verified from 50 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| JUBILANT GENERICS LIMITED | $2.4M | 50 | 100.0% |
SAWAI PHARMACEUTICAL CO.LTD. sources Atorvastatin from 1 verified Indian supplier based on 50 customs records. The primary supplier is JUBILANT GENERICS LIMITED accounting for 100.0% of imports.
How Does SAWAI PHARMACEUTICAL CO.LTD. Compare to Nearest Atorvastatin Importers?
Buyers ranked immediately above and below #15 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | MYLAN PHARMACEUTICALS INC, | UNITED STATES | $5.0M | 99 | $50.0K |
| 18 | APOTEX INC, | CANADA | $4.0M | 81 | $50.0K |
| 15 | SAWAI PHARMACEUTICAL CO.LTD. ★ | JAPAN | $2.4M | 48 | $50.0K |
| 17 | AL-KAWKAB SCIENTIFIC BUREAU | JORDAN | $2.4M | 47 | $50.0K |
SAWAI PHARMACEUTICAL CO.LTD. ranks #15 among 1,291 Atorvastatin importers from India. Average shipment value of $50.0K compared to the market average of $117.9K. The closest competitors by value are MYLAN PHARMACEUTICALS INC, and APOTEX INC,.
Where Does SAWAI PHARMACEUTICAL CO.LTD. Import Atorvastatin To?
Destination countries from 50 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| JAPAN | $2.4M | 50 | 100.0% |
SAWAI PHARMACEUTICAL CO.LTD. imports Atorvastatin to 1 country. The primary destination is JAPAN receiving 100.0% of shipments worth $2.4M.
What Atorvastatin Formulations Does SAWAI PHARMACEUTICAL CO.LTD. Import?
| Formulation | Value | Shipments |
|---|---|---|
| ATORVASTATIN TABLETS 10 mg,BATCH NO#TV22 | $250.0K | 5 |
| ATORVASTATIN TABLETS 10 mg,BATCH#TV22203 | $100.0K | 2 |
| ATORVASTATIN TABLETS 5 mg,BATCH NO#TV122 | $100.0K | 2 |
| ATORVASTATIN TABLETS 5 mg,BATCH NO#TV123 | $100.0K | 2 |
| ATORVASTATIN TABLETS 10 mg,BT#TV222034A | $50.0K | 1 |
| ATORVASTATIN TABLETS 5 mg, BATCH NO#TV12 | $50.0K | 1 |
| ATORVASTATIN TABLETS 10 mg, BATCH NO#TV2 | $50.0K | 1 |
| ATORVASTATIN TABLETS 10 mg, BATCH#TV2230 | $50.0K | 1 |
| ATORVASTATIN TABLETS 5 mg, BATCH#TV12303 | $50.0K | 1 |
| ATORVASTATIN TABLETS 10 mg,BATCH NO:TV225001A TO TV225004A,MFG DT-02.2025,EXP DT-01.2028 | $50.0K | 1 |
SAWAI PHARMACEUTICAL CO.LTD. imports 43 distinct Atorvastatin formulations from India. The top formulation is ATORVASTATIN TABLETS 10 mg,BATCH NO#TV22 with 5 shipments worth $250.0K.
Regulatory Requirements: Importing Atorvastatin into Japan
What SAWAI PHARMACEUTICAL CO.LTD. and other importers must comply with to import Atorvastatin from India
Regulatory Authority
Pharmaceuticals and Medical Devices Agency (PMDA)
Approval Process for Generic Atorvastatin
Generic Drug Application under Japan Pharmaceutical Affairs Act. Requires dissolution and bioequivalence studies per PMDA guidelines. Japanese data bridging often required.
Typical timeline: 12–24 months
GMP Requirements
Japanese GMP (J-GMP) compliance; PMDA on-site inspection of manufacturing facility
Import Licence & Documentation
Marketing Authorization Holder (MAH) must be a Japanese entity; Foreign Manufacturer Registration (Accreditation) required
Labeling & Packaging
Japanese language labeling mandatory; Japanese Pharmacopoeia compliance
Note: Japan requires Yen-denominated pricing approval (NHI drug price listing). Stability data under ICH Zone IVb conditions.
Regulatory information is provided for general reference based on publicly available PMDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with PMDA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Atorvastatin from India and How Much Does SAWAI PHARMACEUTICAL CO.LTD. Import?
India exported $152.2M worth of Atorvastatin through 15,000 shipments from 477 suppliers to 145 countries, serving 1,291 buyers globally. SAWAI PHARMACEUTICAL CO.LTD. imports $2.4M of this total, accounting for 0.3% of India's Atorvastatin exports with 50 shipments from JAPAN. This is verified from 50 customs shipment records covering 43 distinct formulations.
What Is the Average Order Value for SAWAI PHARMACEUTICAL CO.LTD.'s Atorvastatin Imports?
SAWAI PHARMACEUTICAL CO.LTD.'s average Atorvastatin order value is $47.8K per consignment, based on 50 shipments totaling $2.4M. SAWAI PHARMACEUTICAL CO.LTD. is based in JAPAN and ranks #15 among all Atorvastatin importers from India by value. The company sources from 1 verified supplier in India.
Who Supplies Atorvastatin to SAWAI PHARMACEUTICAL CO.LTD.?
SAWAI PHARMACEUTICAL CO.LTD. sources Atorvastatin from 1 verified Indian supplier: JUBILANT GENERICS LIMITED ($2.4M, 100.0%). This is based on 50 customs records.
How Does SAWAI PHARMACEUTICAL CO.LTD. Compare to Other Atorvastatin Importers?
SAWAI PHARMACEUTICAL CO.LTD. ranks #15 among 1,291 Atorvastatin importers from India with a 0.3% market share. The top 3 importers are APL SWIFT SERVICES (MALTA) LTD., ($25.9M), APOTEX CORP ($21.4M), NOVADOZ PHARMACEUTICALS LLC ($17.3M). SAWAI PHARMACEUTICAL CO.LTD. processed 50 shipments from JAPAN.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Atorvastatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Atorvastatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: SAWAI PHARMACEUTICAL CO.LTD. matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as SAWAI PHARMACEUTICAL CO.LTD.'s capped import value divided by total capped export value for Atorvastatin across all Indian exporters.
- 5.Verified Records: This page is backed by 50 individual customs records matching SAWAI PHARMACEUTICAL CO.LTD. importing Atorvastatin, covering 43 formulations from 1 verified supplier.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 145+ countries, 1,291+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Atorvastatin Import Data for SAWAI PHARMACEUTICAL CO.LTD.
Access order-level details, pricing data, supplier connections, and competitive analysis for SAWAI PHARMACEUTICAL CO.LTD.'s Atorvastatin imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SAWAI PHARMACEUTICAL CO.LTD.
Company Profile
Multiple products · $0 total trade · Multiple categories
SAWAI PHARMACEUTICAL CO.LTD. × Atorvastatin
Verified from customs records
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for SAWAI PHARMACEUTICAL CO.LTD..
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Atorvastatin. For current order-level data, contact TransData Nexus.